Research programme: RNA therapeutics - NanoVation Therapeutics/Novo Nordisk
Latest Information Update: 15 Oct 2024
At a glance
- Originator NanoVation Therapeutics
- Developer NanoVation Therapeutics; Novo Nordisk
- Class Cardiovascular therapies; RNA
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cardiovascular disorders; Metabolic disorders; Unspecified